참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Hydrochloric Acid | HCID 313 | — |
| 반응물 | Nilotinib | HCID 644241 | — |
| 용매 | Ethanol | HCID 702 | — |
| 생성물 | Nilotinib Hydrochloride Anhydrous | HCID 16006490 | — |
반응 단계
Nilotinib HCl form T18 as used in any of the processes described in the present application may be prepared according to WO 2010/054056, examples 33-38, which is incorporated herein by reference. For example: To a 1 Liter reactor was added Nilotinib-base form A (20 g, 0.04 mol), absolute ethanol (188 ml) and 13.77% HCl solution in ethanol abs. (10 g, 0.04 mol). The slurry formed thereby was heated to reflux, and dissolution occurred during the stirring. The solution was then filtered under reduced pressure. The filtrate was fed back to the reactor and heated back to reflux. At 76.6° C. the solution was seeded with 0.2 g of dry material obtained by the process of example 23. Precipitation was observed. Then, the solution was maintained at reflux for 1 h, followed by cooling over 2 h to 6° C. At 6° C. ethanol abs. was added (300 ml) and the slurry was stirred at 5° C. for 30 minutes, filtered, washed with ethanol abs. to yield Nilotinib-HCl, form T18.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08937082B2 |
|---|
| 출처 데이터셋 | uspto-grants-2015_01 |
|---|
| ORD ID | ord-b0fc258ed38946c29f720d665d43e19c |
|---|
| 출처 메모 | uspto-grants-2015_01 |
|---|